| 31 |
Bendamustine in Refractory / Relapsed Non Hodgkin Lymphoma |
2021 |
| 32 |
Clinicopathological features of relapsed diffuse large B-cell
lymphoma: South Egypt Cancer Institute experience
|
2021 |
| 33 |
Clinicopathological features of relapsed diffuse large B-cell
lymphoma: South Egypt Cancer Institute experience
|
2021 |
| 34 |
Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin |
2021 |
| 35 |
Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin |
2021 |
| 36 |
Ewing sarcoma outcomes in a country with limited resources: Egypt as an example |
2021 |
| 37 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
2021 |
| 38 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
2021 |
| 39 |
Higher proportion of non-classical and intermediate monocytes in newly diagnosed multiple myeloma patients in Egypt: a possible prognostic marker
|
2021 |
| 40 |
Interleukin-10: A Potential Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma |
2021 |